Shouyao Holding

Shouyao Holdings (Beijing) Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of small molecule innovative drugs. Founded on April 19, 2016, by Chairman and General Manager Li Wenjun, the company has established a comprehensive R&D system that integrates AI drug design, medicinal chemistry, biology, and clinical research. Li, who holds a master's degree in business administration from Peking University, leads the company with the mission to develop affordable Class 1 innovative drugs for patients in China. The core of Shouyao's operations is its subsidiary, CellynTel, which has been engaged in small molecule drug R&D since 2010.

The company's business model encompasses both independent research and collaborative development. For its independent pipeline, Shouyao manages the entire process from drug discovery to commercialization. In its collaborative efforts, primarily with partners like Chia Tai Tianqing Pharmaceutical Group and Shijiazhuang Pharmaceutical Group, Shouyao is responsible for the preclinical discovery and screening of drug candidates. Following this initial stage, the partners handle subsequent clinical development, commercialization, and associated costs, while Shouyao retains co-ownership of intellectual property and rights to milestone payments and future sales royalties. This dual approach allows the company to advance a broad pipeline while managing R&D expenditures. The company went public on the Shanghai STAR Market on March 23, 2022, raising funds to advance its clinical trials and establish a new R&D and industrialization base.

Shouyao's product pipeline is robust and diversified, targeting key oncology indications such as non-small cell lung cancer (NSCLC), lymphoma, hepatocellular carcinoma, and pancreatic cancer, as well as other diseases like type II diabetes. The company's technology platform is centered on small molecule drugs, including proteolysis-targeting chimeras (PROTAC). A leading candidate, SY-707 (conteltinib), is a second-generation ALK inhibitor for ALK-positive NSCLC, which is currently in Phase III trials for first-line treatment and Phase II trials for second-line treatment. Other key pipeline assets include SY-3505, a third-generation ALK inhibitor, and inhibitors targeting KRAS, among others, with multiple products advancing through various stages of clinical trials.

Keywords: Shouyao Holding, biopharmaceutical, small molecule drugs, innovative drug R&D, clinical-stage, oncology, non-small cell lung cancer, ALK inhibitor, drug discovery, clinical trials, pharmaceutical development, cancer therapy, Chia Tai Tianqing, Li Wenjun, CellynTel, conteltinib, SY-707, Shanghai STAR Market, drug pipeline, cancer research, targeted therapy, molecularly targeted drugs, pharmaceutical R&D, China biotech